New Book Announcement –Perspectives in Lung Cancer

Perspectives in Lung Cancer compiles basic and advanced topics on lung cancer pathology and treatment in a single volume. Chapters introduce the reader to chest and lung anatomy followed by the biology of lung cancer. Subsequent chapters delve into diagnostic methods for lung cancer while progressing into treatment options. The book culminates into an explanation of the concept of the Lung Cancer Centre, which is a representation of the editors’ vision for organizing a lung cancer treatment unit.

Key features:

  1. -Organizes key topics covering both standard and avante-garde topics related to lung cancer
  2. -All contributions are presented by experts in lung cancer treatment
  3. -Addresses basic biology of lung cancer
  4. -Provides information about 3D surgical planning, a relatively new concept in the field of thoracic surgery
  5. -Addresses the standard method of resection, VATS and Mini VATS
  6. -Covers the role of radiation and systemic anti-cancer therapies in lung cancer treatment
  7. -Provides a glimpse of modern methods such as image guided surgery and therapy, laser therapy, and photo-dynamic therapy
  8. -Covers the role of palliative care for lung cancer
  9. -Presents information about a visionary organization of a lung cancer unit and treatment centre

The combination of carefully organised chapters covering a wide array of topics make this reference an essential reference for healthcare professionals interested in acquiring a broad perspective on lung cancer treatment with the goal of improving patient outcomes.

Read out the full version here

New Book Announcement – Perspectives in Lung Cancer

Perspectives in Lung Cancer compiles basic and advanced topics on lung cancer pathology and treatment in a single volume. Chapters introduce the reader to chest and lung anatomy followed by the biology of lung cancer. Subsequent chapters delve into diagnostic methods for lung cancer while progressing into treatment options. The book culminates into an explanation of the concept of the Lung Cancer Centre, which is a representation of the editors’ vision for organizing a lung cancer treatment unit.

Key features:

  1. -Organizes key topics covering both standard and avante-garde topics related to lung cancer
  2. -All contributions are presented by experts in lung cancer treatment
  3. -Addresses basic biology of lung cancer
  4. -Provides information about 3D surgical planning, a relatively new concept in the field of thoracic surgery
  5. -Addresses the standard method of resection, VATS and Mini VATS
  6. -Covers the role of radiation and systemic anti-cancer therapies in lung cancer treatment
  7. -Provides a glimpse of modern methods such as image guided surgery and therapy, laser therapy, and photodynamic therapy
  8. -Covers the role of palliative care for lung cancer
  9. -Presents information about a visionary organization of a lung cancer unit and treatment centre

The combination of carefully organised chapters covering a wide array of topics make this reference an essential reference for healthcare professionals interested in acquiring a broad perspective on lung cancer treatment with the goal of improving patient outcomes. Read out the full version here

Abstracts Ahead of Print | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Author(s): Alessandra Bearz, Sara Cecco, Sara Francescon, Francesco Lo Re, Giuseppe Corona, Paolo Baldo*.

 

 

imgpsh_fullsize_anim.png

 

Background: Lung cancer is the most frequent cause of cancer-related death. In the last decades, the introduction of targeted therapies and more recently, of immunotherapy, has led to significant improvements in different outcomes of this malignant neoplasm.

Objective: The present review provides a balanced overview of most recent targeted therapies and immunotherapies patented for the treatment of lung cancer.

Method: An extensive scientific literature and patent databases search were performed to identify peer-reviewed studies containing information on recently patented drugs for the treatment of lung cancer, with a particular focus on their safety data and recently patented combinations.

Results: The development of therapies directed to different pathways involved in the tumor angiogenesis, proliferation, and metastasis has transformed the clinical practice of lung malignancies. Several clinical trials have shown an improvement in terms of progression-free survival and overall survival in patients with advanced/metastatic lung cancer. Safety data, extracted from clinical trials and from the WHO global database of adverse drug reactions (VigiAccessTM database), show that recently patented drugs for the treatment of lung cancer are well- tolerated and most of the adverse events reported are mild to moderate.

Conclusion: Currently, a consistent number of new drugs and combinations have been introduced for the treatment of patients with advanced-stage lung cancer. Safety data remain essential to better assess the long-term risk/benefit ratio of these valuable emerging therapies. The new patents’ development could provide further significant improvements for lung cancer treatment. To read full abstract, please visit: http://www.eurekaselect.com/173895/article

Press Release | Frontiers in clinical drug research — Anti-cancer agents, now in its 5th edition

9789811405150-1

This eBook is authored by Dr. Ata-ur-Rahman, published on June 12, 2019.

For Further Details, Please visit https://ebooks.benthamscience.com/book/9789811405150/

 

Frontiers in Clinical Drug Research – Anti-Cancer Agents brings updated and critical information about developing clinical trials and research in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers.

The fifth volume of the series features reviews on biochemical inhibitors (second-generation protein kinase Inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover neoplasms such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-fic062019.php

The Queensland University of Technology | Inhaled nanoparticles could treat lung cancer

 

Lung cancer sufferers could one day inhale targeted chemotherapy via chitosan nanoparticles, replacing intravenous and oral delivery with a non-invasive, lower dose and better uptake by the body method.

  • Delivering drugs via an inhaler into the lungs is the subject of research around the world
  • Dry powder inhalation of drugs promises a non-invasive, lower dose and better absorption method
  • Chitosan, made from crustacean shells, is biodegradable and is being investigated as a carrier for chemotherapy for lung cancer

https://www.qut.edu.au/news?id=142188

 

QUT pharmaceutical scientist Dr Nazrul Islam, from School of Clinical Sciences, said lung cancer was one of the most common cancers globally and one of the deadliest, being a leading cause of cancer deaths.

He said chitosan had long been investigated for drug delivery and medical applications. It is made from refined crustacean (prawns, crabs, lobster) shells and was an abundant and cheap polymer.

 “Drug delivery directly into the lungs via an inhaler is an efficient way to achieve local and systemic effects of medications,” Dr Islam said.

 

 

“My research is concerned with dry powder inhalation using chitosan nanoparticles loaded with drugs that can reach the lower respiratory tract and from there diffuse into the bloodstream.

“Chitosan is a natural polymer that is known as biodegradable and biocompatible (ie human-cell friendly) and has low toxicity and it can be bound with therapeutic drugs and made into nanoparticles.

“We use different chemical agents called cross-linkers to help form chitosan nanoparticles in which we incorporate drugs, and our concern is whether chitosan nanoparticles formed with some cross-linkers are biodegradable or not.

 “As yet, no studies have conclusively shown complete biodegradation or elimination of chitosan nanoparticles in lung tissue and my research is concerned with finding the form of chitosan that is able to biodegrade in the lungs’ unique tissues.”

Dr Islam said many scientists were investigating the delivery of chemotherapy drugs via the lungs.

 

 

“While many studies have looked at the use of lung delivery of drugs including chemotherapy, gene therapy, vaccines and immunotherapy, none, to my knowledge, has exclusively looked at chitosan as a safe carrier for lung drug delivery,” he said.

 “The reason we study chitosan is also because it has mucoadhesive properties which means it sticks to the lining of the lung cells and it has been found to improve the absorption of therapeutic agents by opening the junctions between cells of the lung lining to allow the drug to target cancer cells.

“Targeted delivery of drugs increases the target tissues’ exposure to the drug while reducing exposure of healthy cells and organs to that drug, which means less toxicity and fewer side-effects.”

Dr Islam said much research suggested chitosan-based nanoparticle drug delivery could be the way of the future to deliver drugs for many different conditions besides lung cancer.

 “We need more research to understand the real-life degradation of chitosan, and identify degradation products and their possible toxicities in the body before we can conduct human trials.

 

 

“We believe chitosan-based nanoparticulate drug delivery has the potential to deliver a large number of therapeutic agents to treat various diseases and open a new era for chitosan-based materials for lung drug delivery and other medical purposes.”

Inhaled micro/nanoparticulate anticancer drug formulations: An emerging targeted drug delivery strategy for lung cancers was published in Current Cancer Drug Targets.

 

 

PODCAST: Chitosan Nano-encapsulation Enhances Gedunin Cytotoxicity

Author(s): Chukwumaobim D.U. Nwokwu, Sameera R. Samarakoon, Desiree N. Karunaratne*, Nuwanthi P. Katuvawila, Meran K. Ediriweera, Kamani H. Tennekoon.

For article details, visit: http://www.eurekaselect.com/154755

Subscribe our YouTube channelhttp://bit.ly/1lr0czy

Article by Disease-“Small-Cell Lung Cancer: Clinical Management and Unmet Needs NEW PERSPECTIVES FOR AN OLD PROBLEM”

Article by Disease on “Lung Cancer”

Abstract: Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed.

Read more: http://benthamscience.com/journals/current-drug-targets/article/141656/

eBook – “Lung Cancer: Clinical and Surgical Specifications”

9781608054428-1

by

Akin E. Balci

Lung cancer diagnosis worldwide has advanced considerably. Progress in diagnostic techniques and therapeutic methods has greatly improved life expectancy in lung cancer patients. Information on lung cancer diagnosis and treatment is therefore useful for all medical professionals especially those who work outside the realm of pulmonology or oncology. This book answers the needs of medical professionals seeking this information and includes both internal and surgical aspects of lung cancer as well as developments in molecular research on pulmonary oncology.

The e-book is divided into several sections which cover basic research on lung cancer epidemiology and carcinogenesis and continue through treatment modalities on non-resectable and advanced stage lung cancer cases (radiofrequency ablation, microwave ablation) and new diagnostic techniques (PET scan). The e-book also contains a section dedicated to surgical treatment options in lung cancer patients. Readers will be able to equip themselves with the necessary medical information for diagnosing lung cancer and treating patients requiring surgery.

Read this insightful ebook here: 

http://ebooks.benthamscience.com/book/9781608054428/

Article by Disease-“Feature Classification and Analysis of Lung Cancer Related Genes through Gene Ontology and KEGG Pathways”

Article by Disease on “Lung Cancer”

Abstract: Characterization of cancer related genes is important and challenging in both biomedicine and computational biology. As one of the leading causes of cancer mortality worldwide, lung cancer accounts for over one million deaths each year. Generally, lung cancer can be assigned to small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Although great advances have been made in lung cancer detection and treatment, 5-year survival rate of patients is still less than 15%. Hence, it is very important to identify all the potential lung cancer related genes as well as their interaction networks. In this research, we presented a novel computational framework to predict lung cancer related genes based on support vector machine (SVM).

14

59 NSCLC related genes and 89 SCLC related genes were retrieved from KEGG pathways, while 2950 non-NSCLC and 4450 non- SCLC genes were randomly selected from Ensembl database. 10 datasets were constructed by dividing the genes into 10 groups. Each gene was encoded by a 13,126-dimensional vector comprised of 12,887 Gene Ontology enrichment scores and 239 KEGG enrichment scores. A feature extraction strategy was applied to obtain an optimal feature set including 400 GO terms and 47 KEGG pathways for NSCLC, 458 GO terms and 27 KEGG pathways for SCLC, respectively. Further feature analysis showed that these optimal features were actively involved in lung tumorigenesis. It also confirms that our method is an effective tool for predicting cancer related genes and has the potential to be applied extensively to the prediction of other types of cancer genes.

Download article: http://benthamscience.com/journals/current-bioinformatics/volume/11/issue/1/page/40/

Article by Disease-“Lung Cancer Chemotherapy, New Treatment and Related Patents”

Article by Disease on “Lung Cancer”

Abstract: The majority of patients with lung cancer present with advanced stage which contributes to death of more people than any other malignancy in the world. The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for non-small cell lung cancer such as erlotinib, gefitinib and crizotinib. Pemetrexed has statistically shown significantly reduced adverse side effects of drug compared with docetaxel. V1801, an analog of gefitinib may overcome gefitinib resistance in patients with non-small cell lung cancer. Thymosin α1, an immunomodulator significantly improves patient’s quality of life by enhancing T-cell function, stimulation of Tcell maturation and differentiation. Various novel compounds and chemotherapeutics were introduced in 2013 patents such as taxane, quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenzamide, cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarbamate, and histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine, picoplatin, and arsenic trioxide in treating small-cell lung cancer.

Read more details: http://benthamscience.com/journals/recent-patents-on-anti-cancer-drug-discovery/article/122274/

%d bloggers like this: